Početna stranicaGNLX • NASDAQ
add
Genelux Corp
Preth. zaklj. cijena
2,42 $
Dnevni raspon
2,43 $ - 2,72 $
Godišnji raspon
1,60 $ - 5,89 $
Tržišna kapitalizacija
99,45 mil. USD
Prosječna količina
192,42 tis.
P/E omjer
-
Prinos dividende
-
Glavno tržište vrijednosnica
NASDAQ
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
| (USD) | pro 2024.info | Godišnja promjena |
|---|---|---|
Prihod | 0,00 | — |
Operativni troškovi | 9,75 mil. | 39,24 % |
Neto dohodak | −8,98 mil. | −32,64 % |
Neto profitabilnost | — | — |
Zarada po dionici | −0,26 | −4,00 % |
EBITDA | −9,69 mil. | −40,33 % |
Efektivna porezna stopa | — | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
| (USD) | pro 2024.info | Godišnja promjena |
|---|---|---|
Gotovinska i kratkoročna ulaganja | 30,90 mil. | 33,22 % |
Ukupna imovina | 34,72 mil. | 24,46 % |
Ukupne obveze | 8,44 mil. | 0,26 % |
Ukupni kapital | 26,27 mil. | — |
Dionice u optjecaju | 34,17 mil. | — |
Cijena prema knjigovodstvenoj vrijednosti | 3,15 | — |
Povrat imovine | −65,00 % | — |
Povrat kapitala | — | — |
Tok novca
Neto promjena novca
| (USD) | pro 2024.info | Godišnja promjena |
|---|---|---|
Neto dohodak | −8,98 mil. | −32,64 % |
Gotovina od poslovanja | −4,30 mil. | 37,74 % |
Gotovina iz ulaganja | 6,67 mil. | 147,87 % |
Gotovina iz financiranja | 91,00 tis. | −77,31 % |
Neto promjena novca | 2,46 mil. | 112,04 % |
Slobodan tok novca | −1,37 mil. | 70,63 % |
Više
Genelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity.
The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.
The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME. Wikipedia
Osnovano
2001
Web-lokacija
Zaposlenici
24
